Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Post-treatment recovery of suboptimal DNA repair capacity and gene expression levels in colorectal cancer patients

J. Slyskova, F. Cordero, B. Pardini, V. Korenkova, V. Vymetalkova, L. Bielik, L. Vodickova, P. Pitule, V. Liska, VM. Matejka, M. Levy, T. Buchler, M. Kubista, A. Naccarati, P. Vodicka,

. 2015 ; 54 (9) : 769-778. [pub] 20140303

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000790

Grantová podpora
NT14329 MZ0 CEP - Centrální evidence projektů

DNA repair in blood cells was observed to be suboptimal in cancer patients at diagnosis, including colorectal cancer (CRC). To explore the causality of this phenomenon, we studied the dynamics of DNA repair from diagnosis to 1 yr follow-up, and with respect to CRC treatment. Systemic CRC therapy is targeted to DNA damage induction and DNA repair is thus of interest. CRC patients were blood-sampled three times in 6-mo intervals, starting at the diagnosis, and compared to healthy controls. DNA repair was characterized by mRNA levels of 40 repair genes, by capacity of nucleotide excision repair (NER), and by levels of DNA strand breaks (SBs). NER and base excision repair genes were significantly under-expressed (P < 0.016) in patients at diagnosis compared to controls, in accordance with reduced NER function (P = 0.008) and increased SBs (P = 0.015). Six months later, there was an increase of NER capacity, but not of gene expression levels, in treated patients only. A year from diagnosis, gene expression profiles and NER capacity were significantly modified in all patients and were no longer different from those measured in controls. All patients were free of relapse at the last sampling, so we were unable to clarify the impact of DNA repair parameters on treatment response. However, we identified a panel of blood DNA repair-related markers discerning acute stage of the disease from the remission period. In conclusion, our results support a model in which DNA repair is altered as a result of cancer.

000      
00000naa a2200000 a 4500
001      
bmc16000790
003      
CZ-PrNML
005      
20190710110355.0
007      
ta
008      
160108s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/mc.22141 $2 doi
035    __
$a (PubMed)24585457
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Slyšková, Jana $u Institute of Experimental Medicine, ASCR, Prague, Czech Republic. First Faculty of Medicine, Institute of Biology and Medical Genetics, Prague, Czech Republic. $7 xx0139415
245    10
$a Post-treatment recovery of suboptimal DNA repair capacity and gene expression levels in colorectal cancer patients / $c J. Slyskova, F. Cordero, B. Pardini, V. Korenkova, V. Vymetalkova, L. Bielik, L. Vodickova, P. Pitule, V. Liska, VM. Matejka, M. Levy, T. Buchler, M. Kubista, A. Naccarati, P. Vodicka,
520    9_
$a DNA repair in blood cells was observed to be suboptimal in cancer patients at diagnosis, including colorectal cancer (CRC). To explore the causality of this phenomenon, we studied the dynamics of DNA repair from diagnosis to 1 yr follow-up, and with respect to CRC treatment. Systemic CRC therapy is targeted to DNA damage induction and DNA repair is thus of interest. CRC patients were blood-sampled three times in 6-mo intervals, starting at the diagnosis, and compared to healthy controls. DNA repair was characterized by mRNA levels of 40 repair genes, by capacity of nucleotide excision repair (NER), and by levels of DNA strand breaks (SBs). NER and base excision repair genes were significantly under-expressed (P < 0.016) in patients at diagnosis compared to controls, in accordance with reduced NER function (P = 0.008) and increased SBs (P = 0.015). Six months later, there was an increase of NER capacity, but not of gene expression levels, in treated patients only. A year from diagnosis, gene expression profiles and NER capacity were significantly modified in all patients and were no longer different from those measured in controls. All patients were free of relapse at the last sampling, so we were unable to clarify the impact of DNA repair parameters on treatment response. However, we identified a panel of blood DNA repair-related markers discerning acute stage of the disease from the remission period. In conclusion, our results support a model in which DNA repair is altered as a result of cancer.
650    _2
$a senioři $7 D000368
650    _2
$a antitumorózní látky $x terapeutické užití $7 D000970
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kolon $x účinky léků $x metabolismus $7 D003106
650    _2
$a kolorektální nádory $x krev $x farmakoterapie $x genetika $7 D015179
650    _2
$a zlomy DNA $x účinky léků $7 D053960
650    12
$a oprava DNA $x účinky léků $7 D004260
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rektum $x účinky léků $x metabolismus $7 D012007
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cordero, Francesca $u University of Torino, Torino, Italy.
700    1_
$a Pardini, Barbara $u Human Genetics Foundation (HuGeF), Torino, Italy.
700    1_
$a Korenková, Vlasta $u Institute of Biotechnology, ASCR, Prague, Czech Republic. $7 _AN042290
700    1_
$a Vymetálková, Veronika $u Institute of Experimental Medicine, ASCR, Prague, Czech Republic. First Faculty of Medicine, Institute of Biology and Medical Genetics, Prague, Czech Republic. $7 xx0102721
700    1_
$a Bielik, Ludovit $u Institute of Experimental Medicine, ASCR, Prague, Czech Republic. First Faculty of Medicine, Institute of Biology and Medical Genetics, Prague, Czech Republic. Faculty of Science, Charles University, Prague, Czech Republic.
700    1_
$a Vodičková, Ludmila $u Institute of Experimental Medicine, ASCR, Prague, Czech Republic. First Faculty of Medicine, Institute of Biology and Medical Genetics, Prague, Czech Republic. $7 xx0128157
700    1_
$a Pitule, Pavel $u Biomedical Centre, Medical School Pilsen, Charles University in Prague, Pilsen, Czech Republic. $7 xx0170503
700    1_
$a Liška, Václav, $u Biomedical Centre, Medical School Pilsen, Charles University in Prague, Pilsen, Czech Republic. Clinic of Oncology and Radiotherapy, Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic. $d 1978- $7 xx0073943
700    1_
$a Matějka, Vít Martin $u Clinic of Oncology and Radiotherapy, Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic. $7 xx0117796
700    1_
$a Levý, Miroslav $u Thomayer Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $7 xx0198664
700    1_
$a Büchler, Tomáš, $u Thomayer Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1974- $7 xx0096851
700    1_
$a Kubista, Mikael $u Institute of Biotechnology, ASCR, Prague, Czech Republic. TATAA Biocenter, Goteborg, Sweden.
700    1_
$a Naccarati, Alessio $u Institute of Experimental Medicine, ASCR, Prague, Czech Republic. Human Genetics Foundation (HuGeF), Torino, Italy.
700    1_
$a Vodička, Pavel $u Institute of Experimental Medicine, ASCR, Prague, Czech Republic. First Faculty of Medicine, Institute of Biology and Medical Genetics, Prague, Czech Republic. $7 xx0060269
773    0_
$w MED00188779 $t Molecular carcinogenesis $x 1098-2744 $g Roč. 54, č. 9 (2015), s. 769-778
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24585457 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20190710110555 $b ABA008
999    __
$a ok $b bmc $g 1103071 $s 924996
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 54 $c 9 $d 769-778 $e 20140303 $i 1098-2744 $m Molecular carcinogenesis $n Mol Carcinog $x MED00188779
GRA    __
$a NT14329 $p MZ0
LZP    __
$a Pubmed-20160108

Najít záznam

Citační ukazatele

Možnosti archivace